277
|
Mutation of PTEN
|
mRNA
|
Humans
|
Deletion found in patients with Biochemical Recurrence
|
Prognostic
|
Biochemical Recurrence Vs no Recurrence
|
p=0.0009
|
Tissue
|
18500259
|
468
|
DNA Ploidy - Diploid
|
Mutation
|
Humans
|
DIPLOID: 5 year disease free survival - (80.5% ); 10 year disease free survival - (72.9%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
469
|
DNA Ploidy - Tetraploid
|
Mutation
|
Humans
|
TETRAPLOID: 5 year disease free survival - (67.8% ); 10 year disease free survival - (61.6%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
470
|
DNA Ploidy - Aneploid
|
Mutation
|
Humans
|
ANUEPLOID: 5 year disease free survival - (49.5% ); 10 year disease free survival - (31.8%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival
|
p<0.001
|
Tissue
|
19633362
|
471
|
DNA Ploidy - Diploid
|
Mutation
|
Humans
|
DIPLOID: 5 year disease free survival - (88.7% ); 10 year disease free survival - (84.8%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
472
|
DNA Ploidy - Tetraploid
|
Mutation
|
Humans
|
TETRAPLOID: 5 year disease free survival - (74.3% ); 10 year disease free survival - (64.7%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
473
|
DNA Ploidy - Anueploid
|
Mutation
|
Humans
|
ANUEPLOID: 5 year disease free survival - (25.0% ); 10 year disease free survival - (0%)
|
Prognostic
|
5 and 10 years disease free survival Vs no survival for Gleason Score=7
|
p<0.001
|
Tissue
|
19633362
|
519
|
EGFR [SNP rs884419]
|
Mutation
|
Humans
|
AG And GG Phenotypes associated with decreased risk of recurrence
|
Prognostic
|
Biochemical recurrence Vs No recurrence
|
A/G Phenotype: p= 0.0018; G/G Phenotype: p = 0.0016
|
Tissue
|
20303520
|
533
|
PSA (G/G Genotype)
|
Mutation
|
Humans
|
Increases risk with G/G Genotype compared with the G/A And A/A genotype
|
Diagnostic
|
Cancer Vs Controls
|
p<0.05
|
Blood
|
20632874
|
534
|
AR: (Short CAG)
|
Mutation
|
Humans
|
Increased Risk with shorter CAG Repeats
|
Diagnostic
|
Cancer Vs Controls
|
p = 0.007
|
Blood
|
20632874
|
535
|
PSA and AR (G/G and Short CAG)
|
Mutation
|
Humans
|
Increased Risk of Prostate Cancer
|
Diagnostic
|
Cancer Vs Controls
|
p = 0.0418
|
Blood
|
20632874
|
536
|
PSA (G/G Genotype)
|
Mutation
|
Humans
|
Increases risk of Gleason Score >=7 with G/G Genotype compared with the G/A & A/A genotype
|
Prognostic
|
Gleason ≤7 Vs Gleason Score >7
|
p= 0.0122
|
Blood
|
20632874
|
537
|
AR: (Short CAG)
|
Mutation
|
Humans
|
Increased RIsk of GS (4+3) with Short CAG Repeats
|
Prognostic
|
Gleason Score 7 (4+3) Vs Gleason Score 7 (3+4)
|
p = 0.045
|
Blood
|
20632874
|
585
|
SLCO2B1 (SNP rs12422149)
|
Mutation
|
Humans
|
Increased risk in GA or AA type allele
|
Prognostic
|
Prostate Cancer Specific Mortality No No mortality
|
p<0.05
|
Blood
|
21266523
|
586
|
SLCO1B3 (SNP rs4149117)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Prostate Cancer Specific Mortality No No mortality
|
p<0.05
|
Blood
|
21266523
|
615
|
Mutation Status of TNFSF10 (SNP: rs3774315 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: 0.0000734; Testing Set: p=0.03
|
Blood
|
21467234
|
616
|
Mutation Status of FBXO34 (SNP: rs8015211 (T/C))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000164
|
Blood
|
21467234
|
617
|
Mutation Status of FBXO34 (SNP: rs12433615 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000406
|
Blood
|
21467234
|
618
|
Mutation Status of FBXO34 (SNP: rs1188069 (T/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000638
|
Blood
|
21467234
|
619
|
Mutation Status of FBXO34 (SNP: rs2341883 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.0000638 ; Testing Set: 0.01
|
Blood
|
21467234
|
620
|
Mutation Status of HERC2 (SNP: rs6497287 (T/C))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000052 ; Test Set: p=0.004
|
Blood
|
21467234
|
621
|
Mutation Status of WWOX (SNP: rs11150069 (C/A))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.00000943
|
Blood
|
21467234
|
622
|
Mutation Status of WWOX (SNP: rs4628973 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000000462
|
Blood
|
21467234
|
623
|
Mutation Status of IL1RAPL1 (SNP: rs225061 (G/T))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
More Aggressive Vs Controls
|
Discovery Set: p= 0.000971
|
Blood
|
21467234
|
624
|
Mutation Status of TNFSF10 (SNP: rs3774315 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
Less Aggressive Vs Controls
|
Discovery Set: 0.0000734; Testing Set: p=0.002
|
Blood
|
21467234
|
625
|
Mutation Status of FBXO34 (SNP: rs2341883 (A/G))
|
Mutation
|
Humans
|
Associated with Disease Aggressiveness
|
Diagnostic
|
Less Aggressive Vs Controls
|
Discovery Set: p= 0.0000638 ; Testing Set: 0.01
|
Blood
|
21467234
|
724
|
Mutation Status of PER1, SNP: rs885747
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
725
|
Mutation Status of PER1, SNP rs2289591 - T/T Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
726
|
Mutation Status of PER1, SNP: rs885747 - G/T + T/T Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
727
|
Mutation Status of PER2, SNP: rs7602358: T/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
728
|
Mutation Status of PER2, SNP: rs7602358: T/G+G/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
729
|
Mutation Status of PER3,SNP: rs1012477: C/G phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
730
|
Mutation Status of PER3,SNP: rs1012477: C/G + C/C phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
731
|
Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
732
|
Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
733
|
Mutation Status of CRY1 SNP: rs12315175 ; C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
734
|
Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
735
|
Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
736
|
Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
737
|
Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
738
|
Mutation Status of CLOCK, SNP: rs11133373, G/G Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
739
|
Mutation Status of CLOCK, SNP: rs11133373, G/G + C/G Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
740
|
Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
741
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
742
|
Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
743
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
744
|
Mutation Status of NPAS2, SNP: rs895521 G/A Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
745
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
746
|
Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs More Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
747
|
Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
748
|
Mutation Status of NPAS2, SNP: rs1369481, T/C + CC Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Cancer
|
p<0.05
|
Blood
|
19934327
|
749
|
Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
750
|
Mutation Status of NPAS2, SNP: rs1369481, C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
751
|
Mutation Status of NPAS2, SNP: rs1369481, T/C+C/C Phenotype
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Controls Vs Less Agressive Disease
|
p<0.05
|
Blood
|
19934327
|
834
|
Mutation Status of StAR
|
Mutation
|
Humans
|
Allelic Loss in StAR in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.00269
|
Tissue
|
22213075
|
835
|
Mutation Status of HSD17B2
|
Mutation
|
Humans
|
Allelic Loss in HSD17B2 in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.031
|
Tissue
|
22213075
|
836
|
Mutation Status of StAR or HSD17B2
|
Mutation
|
Humans
|
Allelic Loss in atleast one (HSD17B2 or StaR) in Recurrence
|
Prognostic
|
Biochemical Recurrenece (5 years)
|
p=0.0028
|
Tissue
|
22213075
|
932
|
Modification Status of RNF219
|
cirDNA
|
Humans
|
Highly modified in PCa Patients (Control: 55%
|
Diagnostic
|
PCA VS no history of prostate disease
|
p=3 *10^-41
|
Plasma
|
22619380
|
933
|
Modification Status of RNF220
|
cirDNA
|
Humans
|
Highly modified in PCa Patients (Control: 55%
|
Diagnostic
|
PCA Vs BPH
|
p = 1 *10^-4
|
Plasma
|
22619380
|
937
|
TMPRSS2:ERG Fusion
|
mRNA
|
Humans
|
Upregulated (RQ = NP: 0.6 Vs LG = 11)
|
Diagnostic
|
Normal adjacent to Prostate (NP) Vs Low Grade PCa
|
<0.005
|
Tissue
|
22674214
|
941
|
Mutation Status of KLK3 (-5429 T/G (rs2569733))
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.013
|
Blood
|
22759231
|
942
|
Mutation Status of KLK2 (Arg250Trp (rs198977))
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: p=0.025 ; Multivariate Analysis : p=0.044
|
Blood
|
22759231
|
943
|
Mutation Status of SULT1A1, Arg213His (rs9282861)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: 0.014
|
Blood
|
22759231
|
944
|
Mutation Status of BGLAP, -198 T/C (rs1800247)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.020
|
Blood
|
22759231
|
945
|
Mutation Status of KLK3 + KLK2 + SULT1A1 + BGLAP + Nonogram
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical Recurrence Vs no Biochemical Recurrence (5 years)
|
p<0.001
|
Blood
|
22759231
|
946
|
Mutation Status of LEPR (LEPR Gln223Arg)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
LEPR Gln223Arg ( A Vs G mutation) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
947
|
Mutation Status of SPP1 (SPP1-66 T>G)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
SPP1 mutaion (SPP1- 66 T>G) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
948
|
Mutation Status of IGF1R (IGF1R+3174 G>A)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
IGF1R mutation (IGF1R+3174 G>A) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
949
|
Mutation Status of IGFBP3 (IGFBP3-202 A>C)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
IGFBP3 mutation (IGFBP3-202 A>C) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
950
|
Mutation Status of FGF2 (FGF2+223 C>T)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
FGF2 mutation (FGF2+223 C>T) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
951
|
Mutation Status of IL6 (IL6-597 G>A)
|
Mutation
|
Humans
|
Increased Risk of PCa
|
Diagnostic
|
IL6 mutation (IL6-597 G>A) in All patients with Prostate Cancer
|
NA
|
NA
|
22792137
|
952
|
Mutation Status of LEPR (LEPR Gln223Arg)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
LEPR Gln223Arg ( A Vs G mutation) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
953
|
Mutation Status of SPP1 (SPP1-66 T>G)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
SPP1 mutaion (SPP1- 66 T>G) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
954
|
Mutation Status of IGF1R (IGF1R+3174 G>A)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
IGF1R mutation (IGF1R+3174 G>A) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
955
|
Mutation Status of IGFBP3 (IGFBP3-202 A>C)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
IGFBP3 mutation (IGFBP3-202 A>C) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
956
|
Mutation Status of FGF2 (FGF2+223 C>T)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
FGF2 mutation (FGF2+223 C>T) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
957
|
Mutation Status of IL6 (IL6-597 G>A)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa
|
Prognostic
|
IL6 mutation (IL6-597 G>A) in Patients with High Grade PCa
|
NA
|
NA
|
22792137
|
958
|
Mutation Status of LEPR (LEPR Gln223Arg)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa for Metastasis
|
Prognostic
|
LEPR Gln223Arg ( A Vs G mutation) in Patients with High Grade PCa With Metastasis
|
NA
|
NA
|
22792137
|
959
|
Mutation Status of SPP1 (SPP1-66 T>G)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa for Metastasis
|
Prognostic
|
SPP1 mutaion (SPP1- 66 T>G) in Patients with High Grade PCa With Metastasis
|
NA
|
NA
|
22792137
|
960
|
Mutation Status of FGF2 (FGF2+223 C>T)
|
Mutation
|
Humans
|
Increased Risk of High Grade PCa for Metastasis
|
Prognostic
|
FGF2 mutation (FGF2+223 C>T) in Patients with High Grade PCa With Metastasis
|
NA
|
NA
|
22792137
|
1089
|
Ribonuclease -L (RNASEL) [Arg462Gln Mutation]
|
Mutation
|
Humans
|
Increased Risk of PCA in African Population
|
Diagnostic
|
Cases Vs Controls
|
p<0.05
|
NA
|
23554651
|
1090
|
Ribonuclease -L (RNASEL) [Arg462Gln Mutation]
|
Mutation
|
Humans
|
Increased Risk of PCA
|
Diagnostic
|
Cases Vs Controls
|
p<0.05
|
NA
|
23554651
|
1143
|
RFX6 (rs339331)
|
Mutation
|
Humans
|
Reduced Risk of Prostate cancer
|
Diagnostic
|
Cancer Vs Normal
|
p= 0.013
|
Blood
|
23803082
|
1146
|
Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;]
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Prostate Cancer Vs Benign Prostatic Hyperplasia
|
NA
|
Tissue
|
23813660
|
1147
|
Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;]
|
mRNA
|
Humans
|
Upregulated in PCa
|
Diagnostic
|
Agressive Vs Non Agressive Prostate Cancer
|
NA
|
Tissue
|
23813660
|
1177
|
Genetic Risk score based on 41 SNPs (rs10187424, rs721048, rs1465618, rs13385191, rs12621278, rs2292884, rs4857841, rs6763931, rs10936632, rs17021918, rs12500426, rs7679673, rs2121875, rs12653946, rs130067, rs1983891, rs339331, rs9364554, rs10486567, rs6465657, rs1512268, rs1447295, rs6983561, rs16901979, rs10086908, rs12543663, rs620861, rs6983267, rs16902094, rs1016343, rs13252298, rs445114, rs10993994, rs4962416, rs10896449, rs11228565, rs12418451, rs10875943, rs9600079, rs4430796, rs11649743, rs1859962, rs8102476, rs17632542, rs2735839, rs9623117, rs5759167, rs5945619, rs5919432)
|
Mutation
|
Humans
|
Increased Score with Increased risk of Prostate Cancer
|
Diagnostic
|
Prostate Cancer Vs no Prostate Cancer
|
Univariate: p=0.014; Multivariate: 0.029
|
Blood
|
23891454
|
1178
|
SLCO2B1 rs12422149 (GG allele)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Time to Progression
|
p =0.028
|
Blood
|
23896625
|
1208
|
RNASEL [D541E variant: GG]
|
Mutation
|
Humans
|
Expressed in patients with High Risk of PCa
|
Prognostic
|
High Risk with GG phenotype Vs High Risk with (TG and TT phenotype)
|
p≤ 0.001
|
Blood
|
24046815
|
1209
|
RNASEL [R462Q variant: AA]
|
Mutation
|
Humans
|
Expressed in patients with High Risk of PCa
|
Prognostic
|
High Risk with AA phenotype Vs High Risk with (AA and GA phenotype)
|
p≤ 0.001
|
Blood
|
24046815
|
1210
|
Copy Number Variation: Deletion of 2p24.3
|
Mutation
|
Humans
|
Deletion found in Hispanic patients with High Risk PCa
|
Prognostic
|
High Risk Vs Low Risk
|
p = 0.007
|
Blood
|
24054869
|
1308
|
C2orf43 [SNP: rs13385191]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.05
|
Blood
|
24411283
|
1309
|
PDLIM5 [SNP: rs17021918]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.01
|
Blood
|
24411283
|
1310
|
JAZF1 [SNP: rs10486567]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.001
|
Blood
|
24411283
|
1311
|
LMTK2 [SNP: rs6465657]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.02
|
Blood
|
24411283
|
1312
|
MSMB [SNP: rs10993994]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.02
|
Blood
|
24411283
|
1313
|
SNP: rs7127900
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.01
|
Blood
|
24411283
|
1314
|
SNP: rs11672691
|
Mutation
|
Humans
|
Increased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.007
|
Blood
|
24411283
|
1315
|
KLK3 [SNP: rs2735839]
|
Mutation
|
Humans
|
Decreased risk of PCa Specific Mortality
|
Prognostic
|
PCa Specific Mortality Vs No Mortality
|
p=0.002
|
Blood
|
24411283
|
1316
|
FRK [SNP: rs171866: AA versus gg/gA]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
Progression Vs No Progression During ADT
|
p=0.015
|
Blood
|
24448834
|
1317
|
DAB2 [SNP: rs268091: GC/CC versus GG]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.012
|
Blood
|
24448834
|
1318
|
DAB2 [SNP: rs268091: CC versus GG/GC]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.031
|
Blood
|
24448834
|
1319
|
EXOC4: [SNP: rs1149558: TT versus CC/CT]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
PCa Specific Mortality Vs No Mortality During ADT
|
p=0.014
|
Blood
|
24448834
|
1320
|
EXOC4: [SNP: rs1149558: TT versus CC/CT]
|
Mutation
|
Humans
|
Increased risk of Progression
|
Prognostic
|
All Cause Mortality Vs No Mortality during ADT
|
p=0.005
|
Blood
|
24448834
|
1354
|
COMT [SNP: rs11705619: T>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.041
|
Blood
|
24682418
|
1355
|
COMT [SNP: rs165849: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.047
|
Blood
|
24682418
|
1356
|
COMT [SNP: rs9332377: C>T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Blood
|
24682418
|
1357
|
CYP1B1 [SNP: rs1800440: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.016
|
Blood
|
24682418
|
1358
|
NQO1 [SNP: rs2917670: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.039
|
Blood
|
24682418
|
1359
|
NQO2 [SNP: rs10223369: C>T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
24682418
|
1360
|
NQO2 [SNP: rs1143684: T>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.030
|
Blood
|
24682418
|
1361
|
NQO2 [SNP: rs6920900 G>C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.007
|
Blood
|
24682418
|
1362
|
SULT2B1 [SNP: rs12460535: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.017
|
Blood
|
24682418
|
1363
|
SULT2B1 [SNP: rs2665582: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.037
|
Blood
|
24682418
|
1364
|
COMT [ SNP: rs16982844: C>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
24682418
|
1365
|
CYP1B1: [SNP: rs1800440: A>G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.0009
|
Blood
|
24682418
|
1366
|
SULT2B1: [SNP: rs10426628: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.025
|
Blood
|
24682418
|
1367
|
SULT2B1: [SNP: rs12460535: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.028
|
Blood
|
24682418
|
1368
|
SULT2B1: [SNP: rs2665582: G>A]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.07
|
Blood
|
24682418
|
1407
|
MIR605 [SNP: rs2043556: GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.006 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.005 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1408
|
MIR605 [SNP: rs2043556: AG/GG vs. AA]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.02
|
Blood
|
24740842
|
1409
|
MIR605 [SNP: rs2043556: GG vs. AA/AG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.02 Cohort 1+2: p=0.03;Multivariate: Cohort 1:p = 0.004 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1410
|
MTRR [SNP: rs9332: CT]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.008 Cohort 1+2: p=0.01
|
Blood
|
24740842
|
1411
|
MTRR [SNP: rs9332: CT/TT vs. CC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.05
|
Blood
|
24740842
|
1412
|
CDON [SNP: rs3737336: CC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1: p= 0.05 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.03 Cohort 2: p = 0.04 Cohort 1+2: p=0.003
|
Blood
|
24740842
|
1413
|
CDON [SNP: rs3737336: CC vs. TT/TC]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
Univariate: Cohort 1+2: p=0.02;Multivariate: Cohort 1: p = 0.03; Cohort 1+2: p=0.007
|
Blood
|
24740842
|
1574
|
RNASEL (SNP: rs635261)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p= 0.002
|
Blood
|
25273821
|
1575
|
XRCC1 (SNP: rs915927)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p=0.009
|
Blood
|
25273821
|
1576
|
AKT1 (SNP: rs2494750)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
PCa-specific mortality Vs No PCa-specific mortality
|
p=0.016
|
Blood
|
25273821
|
1577
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.002
|
Blood
|
25274378
|
1578
|
JAZF1 [SNP: rs10486567]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.012
|
Blood
|
25274378
|
1579
|
(Intergenic) LILRB2–LILRA3 [SNP: rs103294]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score ≤ 6 Vs Gleason Score ≥ 8
|
p=0.024
|
Blood
|
25274378
|
1580
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG/GG)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3)
|
p=0.0002
|
Blood
|
25274378
|
1581
|
(Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG+AA/GG)
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3)
|
p=0.0005
|
Blood
|
25274378
|
1612
|
IL2RB [SNP: rs84460; C vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.006
|
Blood
|
31035590
|
1613
|
SMAD3 [SNP: rs7162912; G vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.0001
|
Blood
|
31035590
|
1614
|
FOXO3 [SNP: rs7762395 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
31035590
|
1615
|
FOXO3 [SNP: rs2153960 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
31035590
|
1616
|
SMAD3 [SNP: rs9302242; A vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.005
|
Blood
|
31035590
|
1617
|
IL4R [SNP: rs1805011; A vs C]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.003
|
Blood
|
31035590
|
1618
|
IL4R [SNP: rs3024586; A vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.003
|
Blood
|
31035590
|
1619
|
CCL5 [SNP: rs2280789 C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.001
|
Blood
|
31035590
|
1620
|
MMP9 [SNP: rs3918262; A Vs G]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.001
|
Blood
|
31035590
|
1621
|
VEGFR2 [SNP: rs7692791; C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.001
|
Blood
|
31035590
|
1622
|
VEGFR2 [SNP: rs2034967; C Vs T]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Overall Survival Vs No Overall Survival
|
p=0.00000008
|
Blood
|
31035590
|
1714
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 GG/AA]
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.003
|
Blood
|
26238235
|
1715
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA]
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
p=0.005
|
Blood
|
26238235
|
1716
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AA vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.032
|
Blood
|
26238235
|
1717
|
TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.002
|
Blood
|
26238235
|
1718
|
TNKS2 (Tankyrase 2) [SNP: rs1539042 CG Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.032
|
Blood
|
26238235
|
1719
|
TNKS2 (Tankyrase 2) [SNP: rs1539042 CG/CC Vs GG]
|
Mutation
|
Humans
|
NA
|
Prognostic
|
Biochemical recurrence Vs No Biochemical Recurrence
|
p=0.02
|
Blood
|
26238235
|
1759
|
AHNAK2; ANKRD30A; ANKRD36C; APOB; ATP13A5; BAI3; CACNA1A; CACNA1E; CDH23; CNTNAP5; EPB41L3; FAM47C; FAT2; FAT4 ;FBN3; FLG2; FRG1B; HSPG2; KMT2D; KRTAP4-9; LPHN3; MUC16; SACS; MUC4; SALL1; MYH11; SCN5A; MYT1L; SPOP; NOD1; SRCAP; PCDHA12; TP53; PIK3CA; TRPM6; PTEN; USH2A; PTH2; ZNF208; PTPRC; ZNF91;RYR1; MUC2;
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
NA
|
29158798
|
1760
|
PSA concentration+Gleason grade+clinical T stage+ AHNAK2; ANKRD30A; ANKRD36C; APOB; ATP13A5; BAI3; CACNA1A; CACNA1E; CDH23; CNTNAP5; EPB41L3; FAM47C; FAT2; FAT4 ;FBN3; FLG2; FRG1B; HSPG2; KMT2D; KRTAP4-9; LPHN3; MUC16; SACS; MUC4; SALL1; MYH11; SCN5A; MYT1L; SPOP; NOD1; SRCAP; PCDHA12; TP53; PIK3CA; TRPM6; PTEN; USH2A; PTH2; ZNF208; PTPRC; ZNF91;RYR1; MUC2;
|
Mutation
|
Humans
|
NA
|
Diagnostic
|
Prostate Cancer Vs No Prostate Cancer
|
NA
|
NA
|
29158798
|
1889
|
Interleukin 8 [SNP: rs4073 A vs T]
|
Mutation
|
Humans
|
Isoform 2 of Eukaryotic translation initiation factor 2â€alpha kinase 4 (4 fold); Keratin type I cytoskeletal 10; SCOâ€spondin (10 fold); Serum amyloid Pâ€component (4 fold); Apolipoprotein(a) (4 fold); Keratin, type I cytoskeletal 9 (3 fold); Ig kappa chain Vâ€IV region (2.4 fold); Isoform 2 of Filamin A (2.4 fold); Keratin, type II cytoskeletal 1(2.6 fold); Keratin, type II cytoskeletal 2 epidermal (2.3 fold);
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.002
|
Blood
|
30641210
|
1890
|
Interleukin 8 [SNP: rs4073 AA vs TT]
|
Mutation
|
Humans
|
Ig heavy chain Vâ€III region BRO (0.1â€fold); Alphaâ€1â€antitrypsin (0.1â€fold); Plasminogen (0.1†fold); Ig heavy chain Vâ€III region TIL (0.1â€fold); Hemopexin (0.1â€fold); Afamin (0.1â€fold); Interâ€alphaâ€trypsin inhibitor heavy chain H1 (0.1â€fold); Protein AMBP (0.1â€fold); Alphaâ€1Bâ€glycoprotein (0.03â€fold); Complement component C8 alpha chain (0.06â€fold);
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.002
|
Blood
|
30641210
|
1891
|
Interleukin 8 [SNP: rs4073 AA vs. TA+TT]
|
Mutation
|
Humans
|
Downregulated in PCa: [4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; ] Upregulated in PCa: [1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone]
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.03
|
Blood
|
30641210
|
1892
|
Interleukin 8 [SNP: rs1126647 TT vs AA]
|
Mutation
|
Humans
|
NA
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.02
|
Blood
|
30641210
|
1893
|
Interleukin 8 [SNP: rs1126647 TT vs AA + AT]
|
Mutation
|
Humans
|
NA
|
Diagnostic/Prognostic
|
Prostate Cancer Vs Benign Prostatic hyperplasia
|
p=0.02
|
Blood
|
30641210
|